Success Stories: Pharmaceutical Bioscience Researcher Earns NIW Approval for Advancing Drug Discovery
Client’s Testimonial:
“I would like to deeply thank you for making this possible! It wouldn’t happen without your help!”
On September 8th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a PhD Student in the Field of Pharmaceutical Bioscience (Approval Notice).
General Field: Computational Astrophysics
Position at the Time of Case Filing: PhD Student
Country of Origin: Iran
Country of Residence at the Time of Filing: Sweden
Approval Notice Date: September 8th, 2025
Processing Time: 1 year, 7 months, 23 days
Case Summary:
Drug development remains one of the costliest and most uncertain areas of healthcare, with nearly 90% of projects failing in clinical trials. This inefficiency delays the availability of effective therapies, drives up costs, and places a heavy burden on healthcare systems and patients alike.
A pharmaceutical bioscience researcher has dedicated her career to addressing this challenge by improving the pre-clinical phase of drug research. She designs and advances in-vitro testing methodologies that enhance precision, streamline timelines, reduce costs, and minimize the need for animal testing. By making early-stage research more reliable and efficient, her work strengthens the entire drug discovery pipeline, ensuring that promising therapies are more likely to succeed in clinical development.
Her contributions have been recognized internationally, with funding support from the Swedish Research Council, the Swedish Brain Foundation, and the Novo Nordisk Foundation. She has also built a strong academic record, authoring six peer-reviewed journal articles (including one first-authored), a first-authored conference abstract, and a co-authored patent application. Her research has been cited 47 times, and she has contributed as a peer reviewer, reflecting professional recognition in her field.
Experts in pharmaceutical science have praised her impact. As one noted, “By offering a standardized approach applicable worldwide, [Client]’s research revolutionizes toxin assessment methodologies, ensuring consistency across product batches. This transformative shift not only contributes to the advancement of neurotoxin research but also promotes a globally ethical and cost-effective approach with far-reaching implications for the field.”
With this track record of innovation and recognition, her EB-2 NIW petition was approved. NAILG carefully prepared and presented the case, securing a successful outcome. With her NIW approval, she is now positioned to continue advancing drug discovery methods that will foster better healthcare outcomes, strengthen the U.S. pharmaceutical industry, and contribute to economic growth.